nejmoa1001122.pdf (498.74 kB)
Download file

Effect of nateglinide on the incidence of diabetes and cardiovascular events

Download (498.74 kB)
journal contribution
posted on 24.10.2012, 09:03 by R. R. Holman, M. A. Bethel, J. J. McMurray, S. M. Haffner, M. J. Davies, R. M. Califf, J. B. Buse, B. Holzhauer, M. Boolell, C. Masson, P. Diem, T. A. Hua, Y. Belenkov, V. Mareev, B. M. Buckley, A. R. Chacra, F-T. Chiang, B. Charbonnel, C-C. Chow, C. Pan, P. Deedwania, D. Einhorn, V. Fonseca, T. Giles, G. R. Fulcher, H. Krum, Z. Gaciong, S. Gaztambide, E. Horton, H. Ilkova, T. Jenssen, S. E. Kahn, M. Laakso, J. Tuomilehto, L. A. Leiter, N. S. Levitt, F. Martinez, I. Sinay, A. S. Villamil, T. Mazzone, E. Meaney, R. Nesto, R. Prager, S. A. Raptis, G. E. H. M. Rutten, H. Sandstroem, F. Schaper, A. Scheen, O. Schmitz, S. Stender, V. Soska, G. Tamás, G. Tognoni, J. Vozár
Background The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. Methods In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program. We followed the participants for a median of 5.0 years for incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was a composite of the individual components of the core composite cardiovascular outcome, hospitalization for unstable angina, or arterial revascularization. Results After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36% and 34%, respectively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P=0.05), the core composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 95% CI, 0.82 to 1.09; P=0.43), or the extended composite cardiovascular outcome (14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P=0.16). Nateglinide did, however, increase the risk of hypoglycemia. Conclusions Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes. (ClinicalTrials.gov number, NCT00097786.)

History

Citation

New England Journal of Medicine, 2010, 362 (16), pp. 1463-1476

Published in

New England Journal of Medicine

Publisher

Massachusetts Medical Society

issn

0028-4793

eissn

1533-4406

Available date

24/10/2012

Publisher version

http://www.nejm.org/doi/full/10.1056/NEJMoa1001122

Language

en

Usage metrics

Categories

Keywords

Exports